Loading...
 
Back to the list
Mediterr J Rheumatol 2024;35(Suppl 1):45-57
Article Links
Diagnosing and Treating Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease as Part of the Still’s Disease Continuum
Apostolos Kontzias1, Olga Petryna2, Priscila Nakasato3, Petros Efthimiou2
Authors Information

1Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, Stony Brook University Hospital, Stony Brook, NY, USA

2Department of Medicine, White Plains Hospital, White Plains, NY, USA

3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

A Kontzias: Affiliation at the time this manuscript was developed. Current affiliation is Amgen, Inc, NY, USA.

P Nakasato: Affiliation at the time this manuscript was developed.

A Kontzias, O Petryna, Nakasato, P Efthimiou

Keywords: systemic juvenile idiopathic arthritis, adult-onset Still’s disease, biologics, autoinflammatory disease, macrophage activation syndrome
References
  1. Jamilloux Y, Gerfaud-Valentin M, Martinon F, Belot A, Henry T, Seve P. Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart. Immunol Res 2015;61(1-2):53-62.
  2. Gurion R, Lehman TJ, Moorthy LN. Systemic arthritis in children: a review of clinical presentation and treatment. Int J Inflam 2012;2012:271569.
  3. Magadur-Joly G, Billaud E, Barrier JH, Pennec YL, Masson C, Renou P, et al. Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis 1995;54(7):587-90.
  4. Bywaters EG. Still's disease in the adult. Ann Rheum Dis 1971;30(2):121-33.
  5. Still GF. On a form of chronic joint disease in children. Med Chir Trans 1897;80:47-60.9.
  6. Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still's disease. J Autoimmun 2018;93:24-36.
  7. Mehta BY, Ibrahim S, Briggs W, Efthimiou P. Racial/Ethnic variations in morbidity and mortality in Adult Onset Still's Disease: An analysis of national dataset. Semin Arthritis Rheum 2019;49(3):469-73.
  8. Aicha BT, Emna H, Olfa S, Selma B, Leila R, Rawda T, et al. Adult-onset and Juvenile-onset Still's Disease: A Comparative Study of Both Sides. Curr Rheumatol Rev 2023;19(2):235-41.
  9. Pay S, Turkcapar N, Kalyoncu M, Simsek I, Beyan E, Ertenli I, et al. A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol 2006;25(5):639-44.
  10. Vercruysse F, Barnetche T, Lazaro E, Shipley E, Lifermann F, Balageas A, et al. Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther 2019;21(1):53.
  11. Nigrovic PA. Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A 2015;112(52):15785-6.
  12. Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008;58(5):1505-15.
  13. Lenert A, Yao Q. Macrophage activation syndrome complicating adult onset Still's disease: A single center case series and comparison with literature. Semin Arthritis Rheum 2016;45(6):711-6.
  14. Minoia F, Davì S, Horne A, Demirkaya E, Bovis F, Li C, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 2014;66(11):3160-9.
  15. Wang R, Li T, Ye S, Tan W, Zhao C, Li Y, et al. Macrophage activation syndrome associated with adult-onset Still's disease: a multicenter retrospective analysis. Clin Rheumatol 2020;39(8):2379-86.
  16. Eloseily EM, Cron RQ. Macrophage activation syndrome. In: Ragab G, T. A, Stoll M, editors. The Microbiome in Rheumatic Diseases and Infection. Cham: Springer; 2018. p. 151-82.
  17. Néel A, Wahbi A, Tessoulin B, Boileau J, Carpentier D, Decaux O, et al. Diagnostic and management of life-threatening Adult-Onset Still Disease: a French nationwide multicenter study and systematic literature review. Crit Care 2018;22(1):88.
  18. Ruscitti P, Cipriani P, Masedu F, Iacono D, Ciccia F, Liakouli V, et al. Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med 2016;14(1):194.
  19. Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2013;65(5):745-52.
  20. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356(23):2361-71.
  21. Delplanque M, Pouchot J, Ducharme-Bénard S, Fautrel BJ, Benyamine A, Daniel L, et al. AA amyloidosis secondary to adult onset Still's disease: About 19 cases. Semin Arthritis Rheum 2020;50(1):156-65.
  22. Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis 2019;78(12):1722-31.
  23. Ruscitti P, Berardicurti O, Iacono D, Pantano I, Liakouli V, Caso F, et al. Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity-characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. Arthritis Res Ther 2020;22(1):151.
  24. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201(9):1479-86.
  25. Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008;67(3):302-8.
  26. Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, et al. Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol 2003;30(11):2422-7.
  27. Rooney T, Murphy E, Benito M, Roux-Lombard P, FitzGerald O, Dayer JM, et al. Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis 2004;63(11):1393-8.
  28. Inoue N, Shimizu M, Tsunoda S, Kawano M, Matsumura M, Yachie A. Cytokine profile in adult-onset Still's disease: Comparison with systemic juvenile idiopathic arthritis. Clin Immunol 2016;169:8-13.
  29. Nirmala N, Brachat A, Feist E, Blank N, Specker C, Witt M, et al. Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J 2015;13:50.
  30. Brachat AH, Grom AA, Wulffraat N, Brunner HI, Quartier P, Brik R, et al. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Res Ther 2017;19(1):13.
  31. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102(7):1369-76.
  32. Moller JC, Paul D, Ganser G, Range U, Gahr M, Kelsch R, et al. IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA). Clin Exp Rheumatol 2010;28(6):912-8.
  33. Stock CJ, Ogilvie EM, Samuel JM, Fife M, Lewis CM, Woo P. Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis. Genes Immun 2008;9(4):349-57.
  34. Sugiura T, Kawaguchi Y, Harigai M, Terajima-Ichida H, Kitamura Y, Furuya T, et al. Association between adult-onset Still's disease and interleukin-18 gene polymorphisms. Genes Immun 2002;3(7):394-9.
  35. Donn RP, Shelley E, Ollier WE, Thomson W, British Paediatric Rheumatology Study G. A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2001;44(8):1782-5.
  36. Wang FF, Huang XF, Shen N, Leng L, Bucala R, Chen SL, et al. A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still's disease. Arthritis Res Ther 2013;15(3):R65.
  37. Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 1991;70(2):118-36.
  38. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore) 2014;93(2):91-9.
  39. Uziel Y, Pomeranz A, Brik R, Navon P, Mukamel M, Press J, et al. Seasonal variation in systemic onset juvenile rheumatoid arthritis in Israel. J Rheumatol 1999;26(5):1187-9.
  40. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011;7(7):416-26.
  41. Ruscitti P, Natoli V, Consolaro A, Caorsi R, Rosina S, Giancane G, et al. Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. Rheumatology (Oxford) 2022;61(10):4124-9.
  42. Gopalarathinam R, Orlowsky E, Kesavalu R, Yelaminchili S. Adult Onset Still's Disease: A Review on Diagnostic Workup and Treatment Options. Case Rep Rheumatol 2016;2016:6502373.
  43. Shenoi S, Wallace CA. Diagnosis and Treatment of Systemic Juvenile Idiopathic Arthritis. J Pediatr 2016;177:19-26.
  44. Kadavath S, Efthimiou P. Adult-onset Still's disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med 2015;47(1):6-14.
  45. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31(2):390-2.
  46. Fautrel B, Zing E, Golmard JL, Le Moel G, Bissery A, Rioux C, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine (Baltimore) 2002;81(3):194-200.
  47. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992;19(3):424-30.
  48. Cush JJ, Medsger TA, Jr., Christy WC, Herbert DC, Cooperstein LA. Adult-onset Still's disease. Clinical course and outcome. Arthritis Rheum 1987;30(2):186-94.
  49. Kontzias A, Efthimiou P. Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances. Drugs 2008;68(3):319-37.
  50. Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R, et al. Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol 2019;46(2):190-7.
  51. Colafrancesco S, Priori R, Valesini G. Presentation and diagnosis of adult-onset Still's disease: the implications of current and emerging markers in overcoming the diagnostic challenge. Expert Rev Clin Immunol 2015;11(6):749-61.
  52. Hinze C, Gohar F, Foell D. Management of juvenile idiopathic arthritis: hitting the target. Nat Rev Rheumatol 2015;11(5):290-300.
  53. Maeno N, Takei S, Nomura Y, Imanaka H, Hokonohara M, Miyata K. Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al. Arthritis Rheum 2002;46(9):2539-41; author reply 41-2.
  54. Fautrel B, Le Moel G, Saint-Marcoux B, Taupin P, Vignes S, Rozenberg S, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J Rheumatol 2001;28(2):322-9.
  55. Ota T, Higashi S, Suzuki H, Eto S. Increased serum ferritin levels in adult Still's disease. Lancet 1987;1(8532):562-3.
  56. Colina M, Zucchini W, Ciancio G, Orzincolo C, Trotta F, Govoni M. The evolution of adult-onset Still disease: an observational and comparative study in a cohort of 76 Italian patients. Semin Arthritis Rheum 2011;41(2):279-85.
  57. Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol 2008;22(5):773-92.
  58. Kudela H, Drynda S, Lux A, Horneff G, Kekow J. Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still's disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity. BMC Rheumatol 2019;3:4.
  59. Mizuta M, Shimizu M, Inoue N, Ikawa Y, Nakagishi Y, Yasuoka R, et al. Clinical significance of interleukin-18 for the diagnosis and prediction of disease course in systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 2021;60(5):2421-6.
  60. de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34(9):1158-63.
  61. Chen DY, Chen YM, Lan JL, Lin CC, Chen HH, Hsieh CW. Potential role of Th17 cells in the pathogenesis of adult-onset Still's disease. Rheumatology (Oxford) 2010;49(12):2305-12.
  62. Wang Z, Chi H, Sun Y, Teng J, Feng T, Liu H, et al. Serum sTREM-1 in adult-onset Still's disease: a novel biomarker of disease activity and a potential predictor of the chronic course. Rheumatology (Oxford) 2020;59(11):3293-302.
  63. Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit LW, et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 2012;71(6):974-80.
  64. Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum 2008;58(12):3924-31.
  65. Bae CB, Suh CH, An JM, Jung JY, Jeon JY, Nam JY, et al. Serum S100A12 may be a useful biomarker of disease activity in adult-onset Still's disease. J Rheumatol 2014;41(12):2403-8.
  66. Kim HA, An JM, Nam JY, Jeon JY, Suh CH. Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in ad.ult-onset Still's disease. J Rheumatol 2012;39(7):1399-406.
  67. Kim HA, Han JH, Kim WJ, Noh HJ, An JM, Yim H, et al. TLR4 Endogenous Ligand S100A8/A9 Levels in Adult-Onset Still's Disease and Their Association with Disease Activity and Clinical Manifestations. Int J Mol Sci 2016;17(8).
  68. Jia J, Wang M, Ma Y, Teng J, Shi H, Liu H, et al. Circulating Neutrophil Extracellular Traps Signature for Identifying Organ Involvement and Response to Glucocorticoid in Adult-Onset Still's Disease: A Machine Learning Study. Front Immunol 2020;11:563335.
  69. Jung J KJ, Suh C, Kim H. Adult Onset Still’s Disease [abstract]. Arthritis Rheumatol 2020;72 (Suppl 10).
  70. Daghor Abbaci K, Ait Hamadouche N, Otmani F, Dahou Makhloufi C, Mechid F, Makrelouf M, et al. Validation of the neutrophil-to-lymphocyte ratio as a new simple biomarker of adult onset Still's disease: A STROBE-Compliant prospective observational study. Medicine (Baltimore) 2022;101(32):e29970.
  71. Shaikh MM, Hermans LE, van Laar JM. Is serum procalcitonin measurement a useful addition to a rheumatologist's repertoire? A review of its diagnostic role in systemic inflammatory diseases and joint infections. Rheumatology (Oxford) 2015;54(2):231-40.
  72. Chen DY, Chen YM, Ho WL, Chen HH, Shen GH, Lan JL. Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still's disease. Ann Rheum Dis 2009;68(6):1074-5.
  73. Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still's disease. Nat Rev Rheumatol 2018;14(10):603-18.
  74. Medsger TA, Jr., Christy WC. Carpal arthritis with ankylosis in late onset Still's disease. Arthritis Rheum 1976;19(2):232-42.
  75. Bjorkengren AG, Pathria MN, Sartoris DJ, Terkeltaub R, Esdaile JM, Weisman M, et al. Carpal alterations in adult-onset Still disease, juvenile chronic arthritis, and adult-onset rheumatoid arthritis: comparative study. Radiology 1987;165(2):545-8.
  76. Sipahi OR, Senol S, Arsu G, Pullukcu H, Tasbakan M, Yamazhan T, et al. Pooled analysis of 857 published adult fever of unknown origin cases in Turkey between 1990-2006. Med Sci Monit 2007;13(7):CR318-22.
  77. Kucukardali Y, Oncul O, Cavuslu S, Danaci M, Calangu S, Erdem H, et al. The spectrum of diseases causing fever of unknown origin in Turkey: a multicenter study. Int J Infect Dis 2008;12(1):71-9.
  78. Kalyoncu U, Solmaz D, Emmungil H, Yazici A, Kasifoglu T, Kimyon G, et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort. J Autoimmun 2016;69:59-63.
  79. Bilgin E, Hayran M, Erden A, Armagan B, Sari A, Kilic L, et al. Proposal for a simple algorithm to differentiate adult-onset Still's disease with other fever of unknown origin causes: a longitudinal prospective study. Clin Rheumatol 2019;38(6):1699-706.
  80. Daghor-Abbaci K, Ait Hamadouche N, Makhloufi CD, Mechid F, Otmani F, Makrelouf M, et al. Proposal of a new diagnostic algorithm for adult-onset Still's disease. Clin Rheumatol 2023;42(4):1125-35.
  81. Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis 2018;77(6):819-28.
  82. Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. Arthritis Rheum 2010;62(8):2530-5.
  83. Woo P, Southwood TR, Prieur AM, Doré CJ, Grainger J, David J, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43(8):1849-57.
  84. Ringold S, Weiss PF, Beukelman T, Dewitt EM, Ilowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res (Hoboken) 2013;65(10):1551-63.
  85. Castaneda S, Blanco R, Gonzalez-Gay MA. Adult-onset Still's disease: Advances in the treatment. Best Pract Res Clin Rheumatol 2016;30(2):222-38.
  86. Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002;46(5):1171-6.
  87. Cavagna L, Caporali R, Epis O, Bobbio-Pallavicini F, Montecucco C. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol 2001;19(3):329-32.
  88. Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis 2001;60 Suppl 3(Suppl 3):iii55-7.
  89. Kokkinos A, Iliopoulos A, Greka P, Efthymiou A, Katsilambros N, Sfikakis PP. Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol 2004;23(1):45-9.
  90. Fautrel B, Sibilia J, Mariette X, Combe B, Club Rhumatismes et I. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005;64(2):262-6.
  91. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Seve P. Adult-onset Still's disease. Autoimmun Rev 2014;13(7):708-22.
  92. Kaneko K, Kaburaki M, Muraoka S, Tanaka N, Yamamoto T, Kusunoki Y, et al. Exacerbation of adult-onset Still's disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration. Int J Rheum Dis 2010;13(4):e67-9.
  93. Agarwal S, Moodley J, Ajani Goel G, Theil KS, Mahmood SS, Lang RS. A rare trigger for macrophage activation syndrome. Rheumatol Int 2011;31(3):405-7.
  94. Maria AT, Le Quellec A, Jorgensen C, Touitou I, Riviere S, Guilpain P. Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 2014;13(11):1149-59.
  95. European Medicines Agency. Tocilizumab summary of product characteristics  [Available from: https://www.ema.europa.eu/en/documents/product-information/roactemra-epar-product-information_en.pdf.
  96. US Food and Drug Administration. Actemra (tocilizumab) injection  [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf.
  97. Castaneda S, Martinez-Quintanilla D, Martin-Varillas JL, Garcia-Castaneda N, Atienza-Mateo B, Gonzalez-Gay MA. Tocilizumab for the treatment of adult-onset Still's disease. Expert Opin Biol Ther 2019;19(4):273-86.
  98. Ma Y, Wu M, Zhang X, Xia Q, Yang J, Xu S, et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still's disease: A meta-analysis. Mod Rheumatol 2018;28(5):849-57.
  99. Sota J, Vitale A, Lopalco G, Pereira RMR, Giordano HF, Antonelli IPB, et al. Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry. Semin Arthritis Rheum 2022;57:152089.
  100. Simeni Njonnou SR, Soyfoo MS, Vandergheynst FA. Efficacy of sarilumab in adult-onset Still's disease as a corticosteroid-sparing agent. Rheumatology (Oxford) 2019;58(10):1878-9.
  101. Anakinra. Australian Public Assessment Report for Anakinra. Available from: https://www.tga.gov.au/file/8613/download Accessed on 05 April 2021.
  102. Kineret. Kineret 100 mg – anakinra: summary of products characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/kineret-epar-product-information_en.pdf. Accessed on 18 November, 2020.
  103. Anakinra. Anakinra for treating Still's disease. Available from: https://www.nice.org.uk/guidance/ta685/documents/129 Accessed on 09 April 2021.
  104. Cavalli G, Franchini S, Aiello P, Guglielmi B, Berti A, Campochiaro C, et al. Efficacy and safety of biological agents in adult-onset Still's disease. Scand J Rheumatol 2015;44(4):309-14.
  105. Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis 2015;10:19.
  106. Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M, et al. A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Front Pharmacol 2016;7:380.
  107. Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. Arthritis Res Ther 2011;13(3):R91.
  108. Ortiz-Sanjuan F, Blanco R, Riancho-Zarrabeitia L, Castaneda S, Olive A, Riveros A, et al. Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review. Medicine (Baltimore) 2015;94(39):e1554.
  109. Schanberg L, Nigrovic P, Cooper A, Chatham W, Akoghlanian S, Singh N, et al. AB1059  A randomized placebo-controlled study of anakinra in patients with Still's disease [abstract]. Ann Rheum Dis 2020;79(Suppl 1):1819-20.
  110. Vastert SJ, Jamilloux Y, Quartier P, Ohlman S, Osterling Koskinen L, Kullenberg T, et al. Anakinra in children and adults with Still's disease. Rheumatology (Oxford) 2019;58(Suppl 6):vi9-vi22.
  111. Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 2014;66(4):1034-43.
  112. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63(2):545-55.
  113. Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, et al. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. Arthritis Rheumatol 2019;71(7):1163-73.
  114. Vitale A, Cavalli G, Ruscitti P, Sota J, Colafrancesco S, Priori R, et al. Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. Front Med (Lausanne) 2020;7:42.
  115. Food and Drug Administration. Arcalyst (rilonacept) injection, for subcutaneous use. Prescribing information. 2008.  [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125249lbl.pdf. Accessed on 19 May, 2021.
  116. Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum 2013;65(9):2486-96.
  117. Petryna O, Cush JJ, Efthimiou P. IL-1 Trap rilonacept in refractory adult onset Still's disease. Ann Rheum Dis 2012;71(12):2056-7.
  118. European Medicines Agency. Ilaris. Summary of Product Characteristics. . Available from: https://www.ema.europa.eu/en/documents/product-information/ilaris-epar-product-information_en.pdf. Accessed on 17 November, 2020.
  119. US Food and Drug Administration. Ilaris (canakinumab) injection 2020 [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125319s097lbl.pdf.
  120. Kedor C, Listing J, Zernicke J, Weiß A, Behrens F, Blank N, et al. Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis 2020;79(8):1090-7.
  121. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367(25):2396-406.
  122. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis 2018;77(12):1710-9.
  123. Brunner HI, Quartier P, Alexeeva E, Constantin T, Koné-Paut I, Marzan K, et al. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study. Arthritis Rheumatol 2020;72(12):2147-58.
  124. Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, et al. Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol 2018;36(4):668-75.
  125. Laskari K, Tektonidou MG, Katsiari C, Athanassiou P, Dimopoulou D, Gerodimos C, et al. Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients. Semin Arthritis Rheum 2021;51(1):137-43.
  126. Vitale A, Berlengiero V, Sota J, Ciarcia L, Ricco N, Barneschi S, et al. Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease. Mediators Inflamm 2020;2020:8054961.
  127. Kontzias A, Efthimiou P. The use of Canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still's disease. Semin Arthritis Rheum 2012;42(2):201-5.
  128. Banse C, Vittecoq O, Benhamou Y, Gauthier-Prieur M, Lequerre T, Levesque H. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease. Joint Bone Spine 2013;80(6):653-5.
  129. Barsotti S, Neri R, Iacopetti V, d'Ascanio A, Talarico R, Tripoli A, et al. Successful treatment of refractory adult-onset still disease with canakinumab: a case report. J Clin Rheumatol 2014;20(2):121.
  130. Lo Gullo A, Caruso A, Pipitone N, Macchioni P, Pazzola G, Salvarani C. Canakinumab in a case of adult onset still's disease: efficacy only on systemic manifestations. Joint Bone Spine 2014;81(4):376-7.
  131. Eriksson P, Jacobs C, Soderkvist P. A patient with a phenotype of adult-onset still disease, but a genotype typical of cryopyrin-associated periodic fever syndrome. J Rheumatol 2013;40(9):1632-3.
  132. Cavalli G, Tomelleri A, De Luca G, Campochiaro C, Dinarello CA, Baldissera E, et al. Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. Arthritis Res Ther 2019;21(1):54.
  133. Klein A, Klotsche J, Hügle B, Minden K, Hospach A, Weller-Heinemann F, et al. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry. Rheumatology (Oxford) 2020;59(9):2287-98.
  134. Cabrera N, Avila-Pedretti G, Belot A, Larbre JP, Mainbourg S, Duquesne A, et al. The benefit-risk balance for biological agents in juvenile idiopathic arthritis: a meta-analysis of randomized clinical trials. Rheumatology (Oxford) 2020;59(9):2226-36.
  135. Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. Ann Rheum Dis 2018;77(6):840-7.
  136. Ladhari C, Jorgensen C, Pers YM. Treatment of refractory adult onset Still's disease with combination anakinra and baricitinib therapy. Rheumatology (Oxford) 2019;58(4):736-7.
  137. Kacar M, Fitton J, Gough AK, Buch MH, McGonagle DG, Savic S. Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease. RMD Open 2020;6(2).
  138. Hu Q, Wang M, Jia J, Teng J, Chi H, Liu T, et al. Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China. Ann Rheum Dis 2020;79(6):842-4.
  139. Honda M, Moriyama M, Kondo M, Kumakura S, Murakawa Y. Tofacitinib-induced remission in refractory adult-onset Still's disease complicated by macrophage activation syndrome. Scand J Rheumatol 2020;49(4):336-8.
  140. Gillard L, Pouchot J, Cohen-Aubart F, Koné-Paut I, Mouterde G, Michaud M, et al. JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Rheumatology (Oxford) 2023;62(4):1594-604.
  141. Sumiyoshi R, Koga T, Shimizu T, Sato S, Tashiro S, Hosogaya N, et al. Single-arm, open-label pilot intervention study to investigate an effect of oral 5-aminolevulinic acid plus sodium ferrous citrate on glucocorticoid reduction in patients with adult-onset Still disease: Study protocol for clinical trial (SPIRIT compliant). Medicine (Baltimore) 2020;99(50):e22708.
  142. Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken) 2022;74(4):521-37.
  143. Fautrel B, Patterson J, Bowe C, Arber M, Glanville J, Mealing S, et al. Systematic review on the use of biologics in adult-onset still's disease. Semin Arthritis Rheum 2023;58:152139.
  144. Consolaro A, Negro G, Lanni S, Solari N, Martini A, Ravelli A. Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clin Exp Rheumatol 2012;30(4 Suppl 73):S157-62.